Search Results

You are looking at 211 - 220 of 521 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti–PD-1–Based Immunotherapy as Curative-Intent Treatment

Jie-Hai Yu, Le-En Liao, Bin-Yi Xiao, Xuan Zhang, Ai-Wen Wu, Yong Cheng, Jing-Hua Tang, Wu Jiang, Ling-Heng Kong, Kai Han, Wei-Jian Mei, Zhi-Gang Hong, Wan-Jun Yang, Dan-Dan Li, Zhi-Zhong Pan, Yun-Feng Li, Xiao-Shi Zhang, and Pei-Rong Ding

inhibitors in non-small cell lung cancer . Nat Commun 2021 ; 12 : 5045 . 32. Eljilany I , Noor A , Paravathaneni M , Granulomatous and sarcoid-like immune-related adverse events following CTLA4 and PD1 blockade adjuvant therapy of melanoma: a

Full access

Uterine Sarcoma, Version 1.2016

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

primary surgery, with adjuvant therapy as indicated. For patients not suitable to receive primary surgery, primary treatment recommendations include systemic therapy and/or pelvic radiation therapy (RT) with or without brachytherapy. Systemic therapy is an

Full access

Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer

Kari E. Hacker, Shitanshu Uppal, and Carolyn Johnston

patients with pathology upgraded to carcinoma were included in analyses. 53 Finally, some gynecologic oncologists recommend completion of surgery after childbearing, because most recurrences are in the contralateral ovary. 56 Adjuvant therapy is

Full access

Advanced Hormone-Sensitive Breast Cancer: Overcoming Resistance

Ingrid A. Mayer

by progressive disease within 6 months of starting treatment with endocrine therapy in the metastatic setting, or the development of metastatic recurrence during or shortly after completing adjuvant therapy. Secondary (acquired) resistance is

Full access

Kidney Cancer: Current and Novel Treatment Options

Eric Jonasch

not support the use of adjuvant therapy for RCC in 2015. With the advent of various antiangiogenic agents and mTOR inhibitors, investigators have moved past the cytokine therapy era, he noted. In the upcoming years, Dr. Jonasch predicted, the next wave

Full access

Disparities in Adjuvant Endocrine Therapy

Elizabeth J. Cathcart-Rake and Kathryn J. Ruddy

: Lessons From Medicare Part D,” in this issue of JNCCN (page 1509 ) adds to the current literature on cancer care disparities in that it reveals how state-level variability in Medicare Part D benefits influence adjuvant therapy prescriptions

Full access

Minimally Invasive Techniques for Treating Gynecologic Malignancies

Amanda N. Fader

extent of adjuvant therapy, and managing locoregional recurrence. In fact, laparoscopy has become the gold standard treatment of many gynecologic conditions, “both benign and malignant,” reported Dr. Fader. Many studies have shown improved outcomes with

Full access

Updates in the Treatment of Bone Cancer

J. Sybil Biermann

extremity: a review of 349 cases from a single institution . Cancer Treat Rev 2010 ; 36 : 1 – 7 . 2. Becker WT Dohle J Bernd L . Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy . J

Full access

Melanoma

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist

Thus, in these high-risk patients, offering SLNB would seem reasonable to help define prognostically homogeneous groups for participation in clinical trials of adjuvant therapy. The significance of tumor regression is debatable, with more recent

Full access

Long-Term Therapy of Venous Thromboembolism in Cancer Patients

Michael B. Streiff

adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group . J Clin Oncol 1996 ; 14 : 2731 – 2737 . 13. Holm T Singnomklao T Rutqvist LE Cedermark B . Adjuvant